In this episode of Hospital Medicine Unplugged, we sprint through thyrotoxicosis and thyroid storm—recognize early, stabilize in the ICU, stop hormone effects fast, and line up definitive therapy.
We open with the do-firsts: high-acuity triage, tele + frequent vitals, broad labs (TSH↓, free T4/T3↑), cultures/CXR/UA if infection suspected, and an immediate search for triggers (infection, surgery, trauma, stopped ATDs, iodinated contrast, amiodarone). Don’t miss mimics—sepsis, sympathomimetic toxicity, serotonin syndrome.
Call the diagnosis clinically and score it: BWPS ≥45 or JTA TS1/TS2 = storm until proven otherwise. Use TRAb for Graves’, ultrasound/Doppler when scintigraphy is out, and thyroglobulin if exogenous hormone is on the table.
Risk reality check: mortality 3.6–25%. High-risk clues—atrial fibrillation, heart failure, hyperpyrexia, CNS dysfunction, hepatic injury, and clear precipitants (especially Graves’, toxic nodules, or abrupt ATD withdrawal). Admit to ICU.
Treatment—build the anti-thyroid storm bundle (give in this sequence):
• β-blocker first for adrenergic control: propranolol PO/IV (also ↓ T4→T3). If decompensated LV failure or bronchospasm, consider esmolol (titrate) or diltiazem for rate control.
• Thionamide to block new synthesis: PTU (LD 500–1000 mg, then 250 mg q4h) or methimazole (60–80 mg/day divided). PTU adds peripheral T4→T3 blockade, but recent data show no mortality advantage vs methimazole—individualize by contraindications and availability.
• Iodide (SSKI or Lugol’s) ≥1 hour after thionamide to block release.
• Glucocorticoid: hydrocortisone 100 mg IV q8h (or dexamethasone) for adrenal support and ↓ T4→T3.
• Cholestyramine 4 g q6–8h as an adjunct in severe or refractory cases.
• Supportive care that matters: acetaminophen + cooling (avoid aspirin), aggressive fluids, nutrition, respiratory support, treat precipitating infection, VTE prophylaxis.
If the backbone buckles (refractory or ATD-intolerant):
• Therapeutic plasma exchange to rapidly lower T3/T4 and bridge to definitive therapy—watch coagulopathy/bleeding.
• Emergent thyroidectomy in experienced hands when medical therapy fails or is contraindicated, or when life-threatening thyrotoxicosis coexists with urgent non-thyroid surgery.
Etiology plays—treat the cause:
• Graves’: ATDs first; long-term low-dose methimazole is reasonable for selected patients.
• Toxic multinodular goiter / toxic adenoma: control with ATDs, then RAI (preferred) or surgery for large goiter/compression.
• Destructive thyroiditis: β-blockers ± steroids; ATDs don’t help.
• Exogenous hormone: stop the source; expect low thyroglobulin.
• Amiodarone-induced thyrotoxicosis (AIT):
– Type 1 (↑ synthesis): high-dose methimazole (± potassium perchlorate in refractory cases).
– Type 2 (destructive): prednisone 40–60 mg/day taper.
– Mixed/unclear: combine thionamide + steroid.
– Continuing amiodarone is individualized with cardiology.
Cardiac complications—don’t miss them:
• Atrial fibrillation is common; prioritize rate control with β-blocker unless contraindicated. Anticoagulate per CHA₂DS₂-VASc, not “because thyrotoxicosis.” Rhythm strategies work better once euthyroid.
Monitoring & de-escalation that sticks:
• Trend free T4/T3 q12–24h early, then space out as the patient settles; watch LFTs/CBC for hepatotoxicity or agranulocytosis.
• Reassess need for iodide after several days; taper β-blocker and steroids with clinical and biochemical improvement.
• For AIT or ongoing amiodarone: check TSH/free T4 every 1–2 weeks, then q4–6 weeks; involve cardiology.
• Pregnancy: PTU in 1st trimester, consider switch to methimazole thereafter; plan definitive therapy pre-conception when possible.
• Elderly/apathetic hyperthyroidism: low-signal presentations—have a low threshold for storm bundle.
Medication pitfalls you don’t want to meet:
• Delaying β-blockade or giving iodide before thionamide (can worsen synthesis).
• Over-β-blockade in shocky patients; use esmolol if tenuous.
• Missing drug-induced causes (amiodarone, immune checkpoint inhibitors, lithium) or biotin assay interference.
We close with the system moves: a thyroid storm pathway that (1) triages to ICU; (2) fires β-blocker → thionamide → iodide → steroid → cholestyramine with weight/renal/liver checks; (3) auto-treats precipitants; (4) flags AF anticoagulation by CHA₂DS₂-VASc; (5) escalates to plasma exchange or surgery when refractory; (6) routes to etiology-specific tracks (Graves’, nodular, thyroiditis, AIT) with multidisciplinary consults; and (7) embeds CBC/LFT safety monitoring.
Fast, guideline-aligned, and complication-aware—recognize storm, sequence therapy right, fix the trigger, and plan definitive control.